Abilify Generic (Aripiprazole) is a neuroleptic drug. Indications and dosage: Abilify Generic (Aripiprazole) is used in the treatment of patients with attacks (acute) of schizophrenia. The drug can also be used for maintenance treatment in people with schizophrenia. Abilify Generic (Aripiprazole)
Tablets can be recommended for the treatment of acute forms of manic episodes that have developed with bipolar disorder of the first type. Abilify Generic (Aripiprazole) can also be used as a supportive treatment for a bipolar disorder of the first type after suffering a mixed or manic episode. Abilify Generic (Aripiprazole) taken orally, regardless of the food. In connection with possible memory impairments, it is recommended to monitor the patient’s use of the drug Abilify Generic (Aripiprazole).
Dosing is determined depending on the nature of the disease, concomitant diseases, and therapy. Dose adjustment is not required for patients over 65 years of age, as well as for patients with impaired liver and kidney functions.
Dosing for schizophrenia: Abilify Generic (Aripiprazole) is prescribed in an initial amount of 10-15 mg/day (take aripiprazole one time per day). Maintenance (average) dose – 15 mg / day. A doctor can adjust the dose, in clinical studies confirmed the effectiveness of aripiprazole in the dose range of 10-30 mg/day. Dosing for manic episodes on the background of bipolar disorders: Abilify Generic (Aripiprazole) is prescribed in the initial dose of 15-30 mg/day (take aripiprazole one time per day).
Changing the dose can be carried out at intervals of 24 hours. A doctor can titrate the treatment, in studies confirmed the efficacy within doses of 15-30 mg/day with a course dose of 3-12 weeks. The efficacy and safety of doses above 30 mg/day have not been evaluated in clinical studies. If patients with bipolar disorders of the first type, as well as mixed episodes or manic episodes against the background of a 6-week course of taking the drug
Abilify Generic (Aripiprazole) (15-30 mg/day) showed no symptoms, such supportive therapy is considered valid. It is necessary to periodically carry out diagnostics to determine the feasibility of further maintenance therapy.
In studies of aripiprazole, there is information about a single dose of 1080 mg, which was accompanied by the development of overdose and had a favorable outcome. With aripiprazole intoxication, patients developed sleepiness, vomiting, weakness, and diarrhea. In patients who were hospitalized due to an overdose of the drug Abilify Generic (Aripiprazole), there were no changes in ECG, laboratory and physiological parameters.
In post-marketing studies, cases of adult patients receiving up to 450 mg of aripiprazole were recorded, after which tachycardia developed. For children with an overdose (a single dose of up to 195 mg), potentially dangerous effects extend, including loss of consciousness and extrapyramidal symptoms.
Treatment of an overdose of the drug Abilify Generic (Aripiprazole) includes symptomatic means, supportive measures (including ensuring normal airway patency, mechanical ventilation, oxygenation). In the treatment of overdose, it is necessary to take into account the clinical symptoms and monitor the function of the cardiovascular system with ECG recording (for the timely detection of rhythm disturbances).
The use of sorbents (in particular activated carbon) for one hour after taking the tablets Abilify Generic (Aripiprazole) orally reduces peak levels of aripiprazole and AUC by 41% and 51%, respectively. The effectiveness of hemodialysis during intoxication with aripiprazole has not been studied, but theoretically (given the degree of association with albumin and the nature of excretion) hemodialysis does not lead to a significant decrease in serum levels of this drug.
The immune system: anaphylaxis From the blood, lymphatic system: leukopenia, thrombocytopenia
The nervous system, brain: dizziness, hallucinations, confusion, cognitive decline, tremor, agitation, ataxia, psychotic symptoms, convulsions, dysarthria, coma, encephalopathy
The gastrointestinal tract: vomiting, abdominal discomfort, diarrhea
The respiratory system: shortness of breath
The hepatobiliary system: a reversible increase in the concentration of functional n testicular, hepatitis
Skin, subcutaneous tissues: skin rashes, photosensitivity, angioedema, urticaria, itching
Kidney, urinary system: kidney dysfunction, acute kidney failure, pain in the kidney area, the formation of precipitates of acyclovir in kidney tubules.
Anemia, microangiopathy, thrombocytopenia in patients with immunodeficiency
Contraindications: When treating tablets with Abilify Generic (Aripiprazole), this may have an undesirable effect on CCC: tachycardia or bradycardia, hypotension (int m including orthostatic), atrioventricular block, myocardial ischemia, phlebitis, beats, palpitations, increased QT-interval, hemorrhage, heart failure, deep vein thrombosis, atrial fibrillation, cardiac arrest.
In rare cases: loss of consciousness, cerebral ischemia, atrial flutter, vasovagal syndrome, thrombophlebitis.
GI: change in appetite, difficulty swallowing, dental caries, flatulence, gastritis, gastroenteritis, gastroesophageal reflux disease, gingivitis, gastrointestinal bleeding, hemorrhoids, weakness of the anal sphincter, colitis, stomatitis, ulceration of the mucous membranes, oral candidiasis, belching, swelling of the tongue, fecal, cholelithiasis, cholecystitis, vomiting, abnormal stool.
In rare cases: increased activity of ALT and AST, pancreatitis, esophagitis, vomiting of blood, bleeding gums, cheilitis, perforation of the gastrointestinal wall, liver enlargement, hepatitis.
Musculoskeletal system: rhabdomyolysis, increased activity of creatine phosphokinase, rheumatoid arthritis, tendonitis, arthritis, tendon bursitis, myopathy, muscle pain, muscle weakness, cramps and muscle twitching, pain in bones and joints.
CNS: extrapyramidal states, dizziness, impaired psychomotor activity, nervousness, depressive states, tremor, hypersalivation, manic and suicidal thoughts, gait disturbances, confusion, hostility, insomnia, akathisia, drowsiness.
In rare cases: hallucinations, buccoglossal syndrome, euphoria, decreased reflexes, obsessive thoughts, dystonia, neuroleptic malignant syndrome, paresthesias, decreased memory and concentration, changes in libido, stupor, amnesia, hyperactivity, panic reactions. Also, the appearance of restless legs syndrome, depersonalization, hyperreflexia, myoclonus, and increased sensitivity to stimuli are possible.
Interaction with other drugs and alcohol
Famotidine has no significant effect on the pharmacokinetic profile of aripiprazole. Potent inhibitors of CYP2 D6 and CYP3 A4 decreased the clearance of aripiprazole during the study. If necessary, the combined use of the drug Abilify Generic (Aripiprazole) with inhibitors of these isoenzymes requires correction (reduction) of the dose of aripiprazole. Abilify Generic (Aripiprazole) does not lead to a significant change in the pharmacokinetics of substrates of CYP2 D6 and CYP3 A4. In the course of research, aripiprazole did not displace warfarin from bonds with proteins. Alcohol is contraindicated during drug treatment.